LSP invests €5m in Kiadis Pharma

The transaction was in the form of a private placement for approximately 3 million ordinary shares at 167 cents per share. As part of it, LSP will receive approximately 1.5 million warrants with a strike price of 232 cents, which can be exercised over a five-year period.

The proceeds from the private placement will be used to fund the development of Kiadis's K-NK cell therapy programmes.

Earlier this week, Kiadis attracted €12m from an unnamed US-based healthcare-focused investment fund.

Previous funding
In June 2007, Kiadis raised €15m in growth capital from MedSciences Capital, LSP, Alta Partners and Quest for Growth. Subsequently, new and existing investors including Draper Esprit, LSP, Alta and Quest for Growth injected €10m into the company in October 2012.

In July 2015, Kiadis went public. The company then attracted €27.6m in post-IPO equity from unknown investors.

Company
Founded in 1997, Kiadis is a biopharmaceutical company developing therapies for patients with life-threatening diseases. It is headquartered in Amsterdam, and has offices across the US. The company employs 120 people, according to LinkedIn. Kiadis is listed on the regulated market of Euronext Amsterdam and Euronext Brussels.

People
Kiadis Pharma – Arthur Lahr (CEO).

Advisers
Company – Bird & Bird (legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• PIPEs
• Healthcare
• Benelux
• Netherlands
• Life Science Partners
• Venture